PRKAA2 and ovarian carcinoma: Inhibition of AMPK expression via silencing of the catalytic AMPK α subunit using specific inhibitors of AMPK or knockout of LKB1, the upstream signal for AMPK activation, reversed the anti-proliferative effects of metformin in breast and ovarian cancer cells [38–40].